APDS patients carry heterozygous gain-of-function mutations in PIK3CD (APDS1) or loss-of-function mutations in PIK3R1 (APDS2), resulting in enhanced PI3K and activated downstream Akt/mTOR signaling. Here, AKT1 is linked to activated PI3K-delta syndrome.